← Back to Search

Tyrosine Kinase Inhibitor

Repotrectinib (TPX-0005) for Solid Tumors

Phase 1

Waitlist Available

Research Sponsored by Turning Point Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 22 days of first repotrectinib dose

Awards & highlights

Study Summary

This trial tests if a new cancer drug works well in people with liver impairment.

Eligible Conditions

Solid Tumors
Metastatic Tumor

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within 22 days of first repotrectinib dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within 22 days of first repotrectinib dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and within 22 days of first repotrectinib dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Area under the plasma concentration-time curve (AUC) of repotrectinib

Maximum Observed Plasma Concentration (Cmax) of repotrectinib

Secondary outcome measures

Evaluate safety and tolerability

Trial Design

1Treatment groups

Experimental Treatment

Group I: Repotrectinib (TPX-0005)Experimental Treatment1 Intervention

Oral repotrectinib (TPX-0005): Cohort 1: Patients with moderate hepatic impairment Cohort 2: Patients with severe hepatic impairment Cohort 3: Patients with normal hepatic function

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Turning Point Therapeutics, Inc.Lead Sponsor

9 Previous Clinical Trials

877 Total Patients Enrolled

Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb

1,508 Previous Clinical Trials

3,370,423 Total Patients Enrolled

Media Library

Repotrectinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05828277 — Phase 1

Solid Tumors Research Study Groups: Repotrectinib (TPX-0005)

Solid Tumors Clinical Trial 2023: Repotrectinib Highlights & Side Effects. Trial Name: NCT05828277 — Phase 1

Repotrectinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05828277 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What sort of safety profile has been identified with Repotrectinib (TPX-0005) thus far?

"Repotrectinib (TPX-0005) has received a score of 1 due to the limited clinical data available concerning its safety and efficacy. This drug is currently in Phase 1 trials."

Answered by AI

How many participants are being taken on for this experiment?

"Indeed, according to clinicaltrials.gov the medical trial initially announced on July 28th 2022 is still open and actively looking for participants. The most recent update was posted on April 25th 2023 and there are 24 spots available at one location."

Answered by AI

Are individuals currently being accepted into this research endeavor?

"Yes, clinicaltrials.gov verifies that this research is currently recruiting participants. This clinical trial was first advertised on July 28th 2022 and its listings were most recently updated April 25th 2023. A total of 24 patients are being sought out from a single medical site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients

2022. "A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05828277.